一线核苷（酸）类似物治疗期间慢性 HBV 感染患者的 HBV RNA 水

StephenW

一线核苷（酸）类似物治疗期间慢性 HBV 感染患者的 HBV RNA 水平
Bei Jiang #1 2，Qinghai Dai #1 2，Yamin Liu 1 2，Guangxin Yu 3，Yuqiang Mi 4 5
隶属关系
隶属关系

     1个
     天津医科大学附属天津市第二人民医院，天津 300192
     2个
     天津市第二人民医院天津市肝病研究所，天津市南开区苏堤南七路，300192，中华人民共和国。
     3个
     北京大学医学部基础医学院微生物与传染病中心，北京，100191，中华人民共和国。
     4个
     天津医科大学附属天津市第二人民医院，天津 300192 [email protected]。
     5个
     天津市第二人民医院天津市肝病研究所，天津市南开区苏堤南七路，300192，中华人民共和国。 [email protected]。

#
贡献相等。

     PMID：36476371 DOI：10.1186/s13027-022-00473-9

抽象的

背景：血清 HBV RNA 被认为是监测慢性乙型肝炎 (CHB) 预后的潜在生物标志物。 然而，缺乏关于一线核苷（酸）类似物（NAs）期间慢性 HBV 感染患者 HBV RNA 概况的真实队列研究。 我们旨在研究 NA 治疗下慢性 HBV 感染患者的 HBV RNA 动态模式和临床价值。

方法：在 82 名初治慢性 HBV 感染患者中测量 HBV RNA 和临床评估。 这些入组患者被分为 HBeAg 阳性慢性 HBV 感染者 (n = 53) 和 HBeAg 阴性慢性 HBV 感染者 (n = 29)。 其中，分别有 59、46 和 30 名慢性 HBV 感染患者在 NAs 治疗的第 12、24 和 48 周完成了随访临床评估。

结果：在初治患者中，HBV RNA 和 HBV DNA、HBsAg 呈正相关（r = 0.602 和 0.502。P < 0.05）。 HBV DNA 的中位水平比 HBV RNA 高 1.64 log10 拷贝/mL。 基线时血清 HBV RNA 的平均水平为 4.62（IQR：3.05-5.82）log10 拷贝/mL，HBV RNA 的中位水平为 2.88（IQR：0-4.67）、2.71（IQR：0-4.22）和 第 12、24 和 48 周分别为 2.96（IQR：0-4.32）log10 拷贝/mL。 在 NA 治疗的第 12、24 和 48 周时，HBV RNA 与 HBV DNA 呈线性正相关（分别为 r = 0.640、0.715 和 0.656，P < 0.05）。 在接受 48 周 NA 治疗的患者中，67% 的 HBV RNA 可量化，而只有 37% 的 HBV DNA 可量化。

结论：HBV RNA 在接受一线 NAs 的慢性 HBV 感染患者的不同阶段具有特征谱。 在抗病毒治疗期间，HBV RNA 仍可监测血清 HBV DNA 检测不到的患者的病毒活性。

关键词：乙肝病毒DNA； 乙肝病毒核糖核酸； 乙肝表面抗原； 乙型肝炎病毒; 核苷（酸）类似物。

© 2022。作者。

StephenW

Levels of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues therapy
Bei Jiang #  1   2 , Qinghai Dai #  1   2 , Yamin Liu  1   2 , Guangxin Yu  3 , Yuqiang Mi  4   5
Affiliations
Affiliations

    1
    Tianjin Second People's Hospital, Tianjin Medical University, Tianjin, 300192, People's Republic of China.
    2
    Tianjin Institute of Hepatology, Tianjin Second People's Hospital, 7th Sudi South Road, Nankai, Tianjin, 300192, People's Republic of China.
    3
    Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, People's Republic of China.
    4
    Tianjin Second People's Hospital, Tianjin Medical University, Tianjin, 300192, People's Republic of China. [email protected].
    5
    Tianjin Institute of Hepatology, Tianjin Second People's Hospital, 7th Sudi South Road, Nankai, Tianjin, 300192, People's Republic of China. [email protected].

#
Contributed equally.

    PMID: 36476371 DOI: 10.1186/s13027-022-00473-9

Abstract

Background: Serum HBV RNA has been considered a potential biomarker in monitoring the prognosis of chronic hepatitis B (CHB). However, Real-life cohort studies on the profile of HBV RNA in chronic HBV infected patients during first-line nucleos(t)ide analogues (NAs) are lacking. We aimed to investigate HBV RNA dynamic pattern and clinical value chronic HBV infected patients under NA therapy.

Methods: HBV RNA and clinical assessments were measured in 82 treatment-naïve chronic HBV infected patients. These enrolled patients were categorized into HBeAg-positive chronic HBV infected (n = 53) and HBeAg-negative chronic HBV infected (n = 29). Of these, there were 59, 46, and 30 chronic HBV infected patients completed the follow-up clinical assessments at 12, 24, and 48 weeks of NAs therapy, respectively.

Results: In treatment-naïve patients, there was a positive correlation between HBV RNA and HBV DNA, HBsAg (r = 0.602 and 0.502. P < 0.05). The median level of HBV DNA was higher than HBV RNA by 1.64 log10 copies/mL. The mean level of serum HBV RNA was 4.62 (IQR: 3.05-5.82) log10 copies/mL at baseline, and the median level of HBV RNA was 2.88 (IQR: 0-4.67), 2.71 (IQR: 0-4.22), and 2.96 (IQR: 0-4.32) log10 copies/mL at week 12, 24, and 48, respectively. HBV RNA showed a positive linear correlation with HBV DNA at 12, 24, and 48 weeks of NA treatment (r = 0.640, 0.715, and 0.656 respectively, P < 0.05). In patients who were treated 48 weeks NAs, 67% had quantifiable HBV RNA while only 37% had quantifiable HBV DNA.

Conclusion: HBV RNA has signature profiles in different stages of chronic HBV infected patients receiving first-line NAs. During antiviral treatment, HBV RNA can still monitor the virus activity in patients whose serum HBV DNA cannot be detected.

Keywords: HBV DNA; HBV RNA; HBsAg; Hepatitis B virus; Nucleos(t)ide analogues.

© 2022. The Author(s).

StephenW

https://infectagentscancer.biome ... /s13027-022-00473-9